Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session 1

186O - Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC)

Date

11 May 2023

Session

Proffered Paper session 1

Topics

Tumour Site

Breast Cancer

Presenters

Tanja Fehm

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101223-101223. 10.1016/esmoop/esmoop101223

Authors

T.N. Fehm1, F. Cottone2, K. Dunton3, F. André4, I. Krop5, Y.H. Park6, M. De Laurentiis7, Y. Miyoshi8, A. Armstrong9, M. Ruiz Borrego10, R. Yerushalmi11, F.P. Duhoux12, T. Takano13, W. Lu14, C. Livings15, A. Egorov14, S. Kim16

Author affiliations

  • 1 Heinrich-Heine-University Düsseldorf, Düsseldorf/DE
  • 2 Daiichi Sankyo, Rome/IT
  • 3 Daiichi Sankyo, Uxbridge/GB
  • 4 Gustave Roussy - Cancer Campus, Villejuif/FR
  • 5 Yale University School of Medicine - Yale Cancer Center, New Haven/US
  • 6 Samsung Medical Center, Seoul/KR
  • 7 Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Università degli Studi di Napoli ”Federico II”, Napoli/IT
  • 8 Hyogo Medical University Hospital, Hyogo/JP
  • 9 Faculty of Biology, Medicine and Health, The University of Manchester, Manchester/GB
  • 10 Hospital Universitario Virgen del Rocio. GEICAM Spanish Breast Cancer Group, 41013 - Seville/ES
  • 11 Rabin Medical Center-Beilinson Campus, Petah Tikva, Tel-Aviv University, Tel-Aviv/IL
  • 12 Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert/BE
  • 13 Cancer Institute Hospital of Japanese Foundation of Cancer Research, Tokyo/JP
  • 14 Daiichi Sankyo, Inc., Basking Ridge/US
  • 15 AstraZeneca Pharmaceuticals, Wilmington/US
  • 16 Asan Medical Center - University of Ulsan College of Medicine, Seoul/KR

Resources

This content is available to ESMO members and event participants.

Abstract 186O

Background

In DESTINY-Breast02 (NCT03523585), T-DXd improved progression-free and overall survival vs TPC in pts with HER2+ mBC who were resistant/refractory to trastuzumab emtansine (T-DM1) (Krop et al. SABCS 2022). Here, we report data on PROs and health-related quality of life (QoL).

Methods

Pts with HER2+ (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization amplified) T-DM1–resistant/refractory mBC were assigned 2:1 to T-DXd or TPC (trastuzumab + capecitabine or lapatinib + capecitabine). PROs were collected and measured at prespecified timepoints using the European Organization for Research and Treatment of Cancer QoL questionnaires (EORTC QLQ)-C30, the breast-cancer–specific EORTC QLQ-BR45 (scored as EORTC QLQ-BR23), and the EuroQol 5-dimension 5-level (EQ-5D-5L) visual analog scale. Change from baseline (CFB) and time to definitive deterioration (TDD) were assessed. QLQ-C30 global health status (GHS)/QoL score was the primary variable of interest.

Results

In the T-DXd (n = 406) and TPC (n = 202) arms (median treatment duration of the safety analysis set: 11.3 vs ∼4.5 mo), questionnaire compliance was >92% at baseline and >76% at cycles 3-29. Mean CFB of GHS/QoL remained stable (within ±10 points) up to cycle 39 for T-DXd and cycle 21 for TPC, after which the number of pts on treatment was not informative (n < 10%). Median TDD was longer with T-DXd vs TPC for GHS/QoL (14.1 vs 5.9 mo; HR, 0.56 [95% CI, 0.44-0.71]) and for all measured QLQ-C30 subscales, including physical functioning (18.7 vs 6.8 mo; HR, 0.46 [95% CI, 0.36-0.60]) and pain (18.7 vs 5.8 mo; HR, 0.38 [95% CI, 0.29-0.49]), with the exception of nausea/vomiting (5.7 vs 6.1 mo; HR, 1.09 [95% CI, 0.86-1.39]). With T-DXd vs TPC, pts experienced prolonged TDD on the QLQ-BR23 arm symptom subscale (18.3 vs 8.8 mo; HR, 0.57 [95% CI, 0.44-0.75]).

Conclusions

Mean CFB in GHS/QoL suggested that overall health and QoL were maintained in T-DXd-treated pts. TDD was longer on all measured QLQ-C30 subscales, except for nausea/vomiting, for pts receiving T-DXd vs TPC. These results continue to support the benefit of T-DXd in pts with T-DM1–resistant HER2+ mBC.

Clinical trial identification

NCT03523585.

Editorial acknowledgement

Under the guidance of authors, assistance in medical writing and editorial support was provided by Caylin Bosch, PhD, and Toinette Labuschagné, PhD, of ApotheCom, and was funded by Daiichi Sankyo, Inc.

Legal entity responsible for the study

Daiichi Sankyo, Inc., and AstraZeneca.

Funding

This study was funded by Daiichi Sankyo, Inc., and AstraZeneca. In March 2019, AstraZeneca entered into a global development and commercialization collaboration agreement with Daiichi Sankyo for trastuzumab deruxtecan (T-DXd; DS-8201).

Disclosure

T.N. Fehm: Financial Interests, Personal, Other, Honoraria: Onkowissen, Medconcept; Financial Interests, Institutional, Other, Honoraria: Novartis, Pfizer, Daiichi Sankyo, Roche, Stemlines, MSD, Pierre Fabre, AstraZeneca. F. Cottone, K. Dunton: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo. F. André: Financial Interests, Institutional, Research Grant: AstraZeneca, Lilly, Novartis, Pfizer, Roche, Daiichi; Financial Interests, Institutional, Other, advisory board: Guardant Health; Financial Interests, Institutional, Other, Advisory board: MEDIMMUNE, Gilead, Relay therapeutics; Other, Founder: Pegacsy. I. Krop: Financial Interests, Personal, Advisory Board: Genentech/Roche, AstraZeneca, Daiichi Sankyo, Macrogenics, Seagen; Financial Interests, Personal, Other, DSMB member: Novartis; Financial Interests, Personal, Other, DSMC member: Merck; Financial Interests, Personal, Full or part-time Employment, Spouse: PureTech, Freeline; Financial Interests, Personal, Stocks/Shares, Spouse: PureTech, Freeline; Financial Interests, Institutional, Invited Speaker: Pfizer, Macrogenics, Genentech, Roche. Y.H. Park: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Lilly, MSD, Eisai, Roche, Daiichi Sankyo, Menarini, Bixink; Financial Interests, Personal, Research Grant: MSD, AstraZeneca, Roche, Pfizer, Novartis; Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo. M. De Laurentiis: Financial Interests, Personal, Invited Speaker: Novartis, Roche, Lilly, MSD, Daiichi Sankyo, AstraZeneca, Pfizer, Menarini, GSK, Gilead; Financial Interests, Personal, Advisory Board: Novartis, Roche, Eli Lilly, MSD, Daiichi Sankyo, AstraZeneca, GSJ, Menarini, Gilead, Seagen. Y. Miyoshi: Financial Interests, Personal, Speaker’s Bureau: Chugai, Eli Lilly, Daiichi Sankyo, Taiho, MAD, Kyowa-Kirin, Eisai, AstraZeneca; Financial Interests, Institutional, Research Grant: Chugai, Eli Lilly, Daiichi Sankyo, Taiho, MAD, Kyowa-Kirin, Eisai, AstraZeneca. A. Armstrong: Financial Interests, Personal, Advisory Board: MSD, Gilead; Financial Interests, Personal, Stocks/Shares, Spouse Shares: AstraZeneca; Financial Interests, Institutional, Funding: AstraZeneca; Financial Interests, Personal, Other, Travel: MSD, Gilead; Financial Interests, Invited Speaker, Travel: Novartis. R. Yerushalmi: Financial Interests, Personal, Invited Speaker: Roche, Teva, Medison, MSD, Astra-Zeneca; Financial Interests, Personal, Advisory Board: Roche, Pfizer, Novartis, AstraZeneca, Gilead. F.P. Duhoux: Financial Interests, Personal, Other, Honoraria: Roche, Pfizer, Lilly, AstraZeneca, Novartis, Amgen, Daiichi Sankyo, Pierre Fabre; Financial Interests, Personal, Other, Travel: Daiichi Sankyo, Gilead, Pfizer, Roche; Financial Interests, Personal, Research Grant: Fondation Belge contre le Cancer. T. Takano: Financial Interests, Personal, Invited Speaker: Daiichi Sankyo, Chugai, Eli Lilly. W. Lu: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo. C. Livings: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. A. Egorov: Financial Interests, Personal, Full or part-time Employment: Daiichi Sankyo; Financial Interests, Personal, Stocks/Shares: Daiichi Sankyo. S. Kim: Financial Interests, Personal, Advisory Board: Novartis, AstraZeneca, Lilly, DaeHwa Pharma, ISU Abx, Daiich-Sankyo, Beigene, HLB Life Science, Samsung Bioepics, OBI pharma; Financial Interests, Personal, Invited Speaker: Legochem Bioscience; Financial Interests, Personal, Ownership Interest: Genopeaks, Neogene TC; Financial Interests, Institutional, Research Grant: Novartis, Sanofi-Genzyme, DongKook Pharm Co. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.